CMPX

MKT CAP:$719M

Compass Therapeutics, Inc.

Market Cap

$719M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$5.32+$0.15 (+2.90%)

Apr 22, 2026

Company Details

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of developmen...

CEO

Thomas J. Schuetz

IPO Date

Apr 5, 2021

Website

www.compasstherapeutics.com

Key Metrics TTM

Revenue

$0

-100.0% YoY

Net Income

-$66M

EPS (Diluted)

-$0.45

Free Cash Flow

-$49M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 14, 2026

PENDING

FY 2025

Mar 5, 2026

$0-100.0%EPS -$0.42

Q4 2025

Mar 5, 2026

$0EPS -$0.09

Q3 2025

Nov 5, 2025

$0EPS -$0.10

Q2 2025

Aug 11, 2025

$0-100.0%EPS -$0.14

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$7M
Q2 22	$0	$0	-$9M
Q3 22	$0	$0	-$13M
Q4 22	$0	$0	-$13M
Q1 23	$0	$0	-$10M
Q2 23	$0	$0	-$13M
Q3 23	$0	$0	-$12M
Q4 23	$0	$0	-$15M
Q1 24	$0	$0	-$13M
Q2 24	$850.0K	$850.0K	-$15M
Q3 24	$0	$0	-$12M
Q4 24	$0	$0	-$17M
Q1 25	$0	$0	-$18M
Q2 25	$0	$0	-$21M
Q3 25	$0	$0	-$16M
Q4 25	$0	$0	$0

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	846.0x	—
Q3 24	846.0x	—
Q4 24	846.0x	—
Q1 25	846.0x	—
Q2 25	—	—
Q3 25	—	—
Q4 25	—	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$8M	-$8M
Q2 22	-$5M	-$5M
Q3 22	-$11M	-$11M
Q4 22	-$11M	-$11M
Q1 23	-$12M	-$12M
Q2 23	-$10M	-$10M
Q3 23	-$6M	-$6M
Q4 23	-$12M	-$12M
Q1 24	-$14M	-$14M
Q2 24	-$11M	-$11M
Q3 24	-$11M	-$11M
Q4 24	-$9M	-$9M
Q1 25	-$13M	-$13M
Q2 25	-$12M	-$12M
Q3 25	-$11M	-$11M
Q4 25	-$13M	-$13M

Capital Expenditures

Quarter	CapEx
Q1 22	$194.0K
Q2 22	$131.0K
Q3 22	$27.0K
Q4 22	$54.0K
Q1 23	$0
Q2 23	$11.0K
Q3 23	$10.0K
Q4 23	$9.0K
Q1 24	$0
Q2 24	$0
Q3 24	$44.0K
Q4 24	$0
Q1 25	$18.0K
Q2 25	$0
Q3 25	$7.0K
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	-2.1%
Q2 22	—	-83.9%
Q3 22	—	+115.2%
Q4 22	—	-0.9%
Q1 23	—	+35.2%
Q2 23	—	+48.4%
Q3 23	—	-5.3%
Q4 23	—	+19.4%
Q1 24	—	+31.5%
Q2 24	—	+19.2%
Q3 24	—	+2.6%
Q4 24	—	+7.7%
Q1 25	—	+40.7%
Q2 25	-100.0%	+32.5%
Q3 25	—	+29.2%
Q4 25	—	-100.0%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$2M	—
Q2 22	$1M	—
Q3 22	$1M	—
Q4 22	$1M	—
Q1 23	$1M	—
Q2 23	$2M	—
Q3 23	$2M	—
Q4 23	$2M	—
Q1 24	$2M	—
Q2 24	$2M	249.5%
Q3 24	$2M	—
Q4 24	$2M	—
Q1 25	$3M	—
Q2 25	$3M	—
Q3 25	$1M	—
Q4 25	$2M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$4M	$3M
Q2 22	$6M	$3M
Q3 22	$10M	$3M
Q4 22	$10M	$3M
Q1 23	$7M	$3M
Q2 23	$10M	$3M
Q3 23	$9M	$3M
Q4 23	$12M	$3M
Q1 24	$10M	$3M
Q2 24	$11M	$5M
Q3 24	$9M	$4M
Q4 24	$13M	$4M
Q1 25	$13M	$5M
Q2 25	$16M	$5M
Q3 25	$13M	$3M
Q4 25	$14M	$4M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$136M	$0	$136M
Q2 22	$26M	$106M	$132M
Q3 22	$16M	$104M	$121M
Q4 22	$35M	$152M	$187M
Q1 23	$27M	$148M	$175M
Q2 23	$19M	$149M	$169M
Q3 23	$30M	$133M	$164M
Q4 23	$24M	$128M	$152M
Q1 24	$24M	$133M	$156M
Q2 24	$19M	$127M	$146M
Q3 24	$37M	$99M	$135M
Q4 24	$43M	$83M	$127M
Q1 25	$41M	$72M	$113M
Q2 25	$23M	$78M	$101M
Q3 25	$46M	$174M	$220M
Q4 25	$31M	$178M	$209M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	101M	+94.3%	+96.6%
Q2 22	101M	+0.1%	+94.5%
Q3 22	101M	+0.1%	+63.7%
Q4 22	105M	+4.1%	+102.6%
Q1 23	126M	+20.1%	+25.3%
Q2 23	127M	+0.3%	+25.5%
Q3 23	127M	+0.5%	+26.1%
Q4 23	128M	+0.2%	+21.4%
Q1 24	137M	+7.0%	+8.1%
Q2 24	138M	+0.7%	+8.6%
Q3 24	138M	0.0%	+8.0%
Q4 24	137M	-0.7%	+7.0%
Q1 25	138M	+1.2%	+1.2%
Q2 25	138M	+0.0%	+0.5%
Q3 25	138M	0.0%	+0.5%
Q4 25	185M	+33.7%	+35.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	24
Q2 22	$0	24
Q3 22	$0	24
Q4 22	$0	26
Q1 23	$0	26
Q2 23	$0	26
Q3 23	$0	26
Q4 23	$0	32
Q1 24	$0	32
Q2 24	$26.6K	32
Q3 24	$0	32
Q4 24	$0	43
Q1 25	$0	43
Q2 25	$0	43
Q3 25	$0	43
Q4 25	$0	39

Revenue / Employee